Liver Transplant

Gastroenterology
6
Pipeline Programs
4
Companies
37
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
1
3
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
4 programs
1
2
Cyclosporine microemulsionPhase 41 trial
Cyclosporine microemulsionPhase 41 trial
Minimisation of TACPhase 31 trial
Group 1 Donor Specific RegulationN/A1 trial
Active Trials
NCT01230502Terminated11Est. Jun 2012
NCT02040584Completed217Est. Feb 2016
NCT00171509Completed61Est. Oct 2005
+1 more trials
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
PegasysPhase 45 trials
Active Trials
NCT01679834Completed7,500Est. Jul 2017
NCT01697501Completed88Est. Jun 2013
NCT01886300Terminated16Est. May 2013
+2 more trials
United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
1
treprostinil sodiumPhase 2/31 trial
Active Trials
NCT01884038Withdrawn0Est. Jun 2010
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
Immunosuppression withdrawalPhase 21 trial
Active Trials
NCT02533180CompletedEst. Jul 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
RochePegasys
RochePegasys
RochePegasys
RochePegasys
RochePegasys
RochePegasys
NovartisCyclosporine microemulsion
NovartisCyclosporine microemulsion
RochePegasys
RochePegasys
RochePegasys
NovartisMinimisation of TAC
RochePegasys
RochePegasys
RochePegasys

Showing 15 of 37 trials with date data

Clinical Trials (37)

Total enrollment: 14,057 patients across 37 trials

NCT00436163RochePegasys

A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B

Start: Mar 2007Est. completion: May 201039 patients
Phase 4Completed
NCT00800748RochePegasys

A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C

Start: Feb 2006Est. completion: Jan 2009372 patients
Phase 4Completed
NCT02598063RochePegasys

A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B

Start: Oct 2005Est. completion: Apr 2009255 patients
Phase 4Completed
NCT00207311RochePegasys

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus

Start: Aug 2005Est. completion: May 200930 patients
Phase 4Completed
NCT02570191RochePegasys

A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)

Start: Nov 2004Est. completion: Feb 200760 patients
Phase 4Completed
NCT00275548RochePegasys

Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C

Start: Jul 2004Est. completion: Apr 200912 patients
Phase 4Completed
NCT00171509NovartisCyclosporine microemulsion

Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients

Start: May 2004Est. completion: Oct 200561 patients
Phase 4Completed
NCT00171743NovartisCyclosporine microemulsion

Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients

Start: Apr 2004Est. completion: Jan 200647 patients
Phase 4Completed
NCT02864199RochePegasys

A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

Start: Feb 2004Est. completion: Sep 200763 patients
Phase 4Completed
NCT00077649RochePegasys

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

Start: Jan 2004Est. completion: Dec 2005188 patients
Phase 4Completed
NCT02604823RochePegasys

A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)

Start: Nov 2003Est. completion: Nov 2005307 patients
Phase 4Completed
NCT02040584NovartisMinimisation of TAC

A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.

Start: Dec 2013Est. completion: Feb 2016217 patients
Phase 3Completed
NCT01697501RochePegasys

A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253

Start: Nov 2012Est. completion: Jun 201388 patients
Phase 3Completed
NCT00336518RochePegasys

Continuing Treatment With Pegasys and Copegus

Start: Jun 2006Est. completion: Jul 2009100 patients
Phase 3Unknown
NCT02732639RochePegasys

A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)

Start: Oct 2005Est. completion: Dec 200831 patients
Phase 3Completed
NCT02762383RochePegasys

Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)

Start: Mar 2005Est. completion: Jun 200919 patients
Phase 3Terminated
NCT02806505RochePegasys

HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)

Start: Jun 2004Est. completion: Aug 200781 patients
Phase 3Completed
NCT00122616RochePegasys

Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C

Start: Nov 2003Est. completion: Mar 200952 patients
Phase 3Completed
NCT02736721RochePegasys

Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)

Start: Sep 2003Est. completion: Nov 201041 patients
Phase 3Completed
NCT01853254RochePegasys

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Start: Sep 2003Est. completion: Sep 2011272 patients
Phase 3Completed
NCT00048945RochePegasys

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Start: Jan 2002Est. completion: Oct 2004820 patients
Phase 3Completed
NCT01884038United Therapeuticstreprostinil sodium

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Start: Jun 2008Est. completion: Jun 20100
Phase 2/3Withdrawn
NCT02533180Allergy TherapeuticsImmunosuppression withdrawal

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation

Start: Dec 2015Est. completion: Jul 2022
Phase 2Completed
NCT01331850RochePegasys

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Start: May 2011Est. completion: Jan 2013381 patients
Phase 2Completed
NCT00442572RochePegasys

SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).

Start: Jul 2006Est. completion: Apr 201221 patients
Phase 2Completed
NCT01679834RochePegasys

An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C

Start: Nov 2014Est. completion: Jul 20177,500 patients
N/ACompleted
NCT01886300RochePegasys

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam

Start: Sep 2012Est. completion: May 201316 patients
N/ATerminated
NCT01750216RochePegasys

An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1

Start: Jul 2012Est. completion: Jan 2015196 patients
N/ACompleted
NCT01604291RochePegasys

An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C

Start: May 2012Est. completion: Feb 2016991 patients
N/ACompleted
NCT01508130RochePegasys

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Start: Jan 2012Est. completion: Mar 2014672 patients
N/ACompleted
NCT01230502NovartisGroup 1 Donor Specific Regulation

Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation

Start: Nov 2011Est. completion: Jun 201211 patients
N/ATerminated
NCT01667432RochePegasys

An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B

Start: Jul 2011Est. completion: Aug 2014141 patients
N/ACompleted
NCT01392742RochePegasys

An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin

Start: May 2011Est. completion: Jul 2014443 patients
N/ACompleted
NCT01645969RochePegasys

A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML22265

Start: Apr 2011Est. completion: Oct 201265 patients
N/ACompleted
NCT01416610RochePegasys

An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy

Start: Apr 2010Est. completion: Oct 201488 patients
N/ACompleted
NCT01283074RochePegasys

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B (Perseas)

Start: May 2009Est. completion: Nov 2012107 patients
N/ACompleted
NCT02556307RochePegasys

A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients

Start: Mar 2009Est. completion: Jul 2014270 patients
N/ACompleted

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
7h ago

Key Account Director, Diagnostics and Research

Tempus
Remote
20h ago
$150K - $200K/yr

Experienced Clin Programmer

Johnson & Johnson
High Wycombe, Buckinghamshire, United Kingdom
20h ago

[Innovative Medicine] Director, Government Affairs and Policy Dept., Integrated Market Access Div.

Johnson & Johnson
Chiyoda, Tokyo, Japan
20h ago

Analyst Accounting

Johnson & Johnson
Suzhou, Jiangsu, China
20h ago

Lead Product Security Engineer

Johnson & Johnson
Danvers, Massachusetts, United States of America
20h ago
$94K - $152K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Irritable Bowel Syndrome(29)Gastroesophageal Reflux(27)Liver Transplantation(24)Celiac Disease(23)Hepatic Insufficiency(22)Liver Cirrhosis(22)Gastroesophageal Reflux Disease (GERD)(14)Hepatic Encephalopathy(12)